Arvinas

Arvinas is a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins using its proprietary PROTAC (PROteolysis TArgeting Chimeras) protein degradation platform. The company's lead programs are centered around the receptors associated with prostate and breast cancers.

Arvinas' most advanced product candidate is vepdegestrant (ARV-471), an orally bioavailable PROTAC protein degrader designed to degrade the estrogen receptor (ER) for treating ER+/HER2- metastatic breast cancer. In July 2021, Arvinas entered a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant, sharing costs and profits equally. Vepdegestrant is being evaluated as a monotherapy and in combination with other therapies across multiple treatment settings for ER+/HER2- metastatic breast cancer.

Another key asset is ARV-766, Arvinas' second-generation PROTAC androgen receptor (AR) degrader for metastatic castration-resistant prostate cancer (mCRPC). In April 2024, Arvinas entered an exclusive license agreement with Novartis for ARV-766's worldwide development and commercialization, receiving a USD 150 million upfront payment and eligible for up to USD 1.01 billion in milestones and royalties. ARV-766 has shown preclinical activity against tumors with wild-type and mutated AR.

Arvinas' pipeline also includes bavdegalutamide (ARV-110), an AR degrader for mCRPC, and ARV-102, a PROTAC degrader targeting LRRK2 for neurodegenerative diseases like Parkinson's. As of March 2024, Arvinas had cash, cash equivalents, and marketable securities of USD 1.2 billion, expected to fund operations into 2027.

Since September 2018, Arvinas has been operating as a publicly listed company and is traded on Nasdaq under the ticker symbol ARVN.

Key customers and partnerships

In its strategic collaboration with Pfizer, both companies are jointly developing and will co-commercialize vepdegestrant. Arvinas has also partnered with Bayer, Genentech (Roche), and established the Oerth Bio joint venture for additional programs.

Through the exclusive license agreement signed in April 2024 , Novartis gained worldwide rights to develop and commercialize ARV-766 and Arvinas' preclinical AR-V7 program for mCRPC.